Purchase this article with an account.
Y.R. Chu, M. Sell; Clinical Evaluation of Ocular Surface Toxicity of Ketorolac Tromethamine 0.4% (Acular LS®) vs. Bromfenac 0.09% (Xibrom®) Ophthalmic Solution . Invest. Ophthalmol. Vis. Sci. 2006;47(13):74.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate potential ocular surface toxicity associated with two recently introduced NSAIDs, ketorolac tromethamine 0.4% (Acular LS) and (Xibrom) bromfenac 0.09%.
Single–center, open label clinical study of 20 healthy eyes of 10 patients. Each subject received bromfenac 0.09% (Xibrom) in the right eye and ketorolac tromethamine 0.4% (Acular LS) in the left eye for three weeks. Dosing was twice–daily the first week, four–times–daily the second week, and six–times–daily the third week. Corneal staining with fluorescein and conjunctival staining with lissamine green were performed at each study visit (baseline and weeks 1,2, and 3).
At every follow–up visit, eyes receiving bromfenac had greater amounts of conjunctival staining than eyes treated with ketorolac. At week 1, the mean staining score was 2.3 with ketorolac and 4.5 with bromfenac. At week 2, mean scores were 1.9 with ketorolac and 4.5 with bromfenac. At week 3, mean conjunctival staining scores were 1.8 with ketorolac, and 4.3 with bromfenac. There were no differences between ketorolac and bromfenac in corneal staining.
Ketorolac tromethamine 0.4% was less toxic to the ocular surface than bromfenac 0.09%.
This PDF is available to Subscribers Only